Leerink Partnrs upgraded shares of Enhabit (NYSE:EHAB - Free Report) from a strong sell rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Enhabit's Q3 2024 earnings at $0.04 EPS, FY2024 earnings at $0.20 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.03 EPS.
A number of other research firms also recently weighed in on EHAB. SVB Leerink upgraded Enhabit from an underperform rating to a market perform rating and set a $8.50 target price on the stock in a report on Tuesday. Oppenheimer reaffirmed a market perform rating on shares of Enhabit in a research note on Thursday, March 7th. Jefferies Financial Group cut shares of Enhabit from a buy rating to a hold rating and dropped their target price for the company from $14.00 to $8.75 in a report on Thursday, May 9th. Finally, UBS Group upgraded shares of Enhabit from a sell rating to a neutral rating and set a $9.50 price target for the company in a research note on Thursday, March 7th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of $10.13.
View Our Latest Stock Report on EHAB
Enhabit Trading Down 4.4 %
Enhabit stock traded down $0.39 during trading hours on Tuesday, reaching $8.65. The company had a trading volume of 654,897 shares, compared to its average volume of 596,102. The firm has a market cap of $433.55 million, a price-to-earnings ratio of -5.44, a P/E/G ratio of 1.41 and a beta of 1.98. Enhabit has a 12-month low of $7.12 and a 12-month high of $14.59. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.50 and a quick ratio of 1.50. The company has a 50-day moving average price of $10.39 and a 200 day moving average price of $10.07.
Enhabit (NYSE:EHAB - Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The business had revenue of $260.60 million for the quarter, compared to analyst estimates of $260.30 million. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. During the same quarter last year, the firm earned $0.32 EPS. Equities analysts forecast that Enhabit will post 0.24 earnings per share for the current year.
Insider Activity at Enhabit
In other news, Director Jeffrey Bolton purchased 10,000 shares of Enhabit stock in a transaction that occurred on Friday, May 10th. The stock was bought at an average price of $8.24 per share, with a total value of $82,400.00. Following the completion of the transaction, the director now directly owns 42,299 shares of the company's stock, valued at $348,543.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.90% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. JANA Partners Management LP bought a new position in Enhabit in the third quarter valued at about $20,532,000. UBS Group AG lifted its stake in shares of Enhabit by 7,973.5% in the 3rd quarter. UBS Group AG now owns 1,633,751 shares of the company's stock worth $18,380,000 after purchasing an additional 1,613,515 shares during the period. Ancora Advisors LLC boosted its holdings in shares of Enhabit by 414.5% in the third quarter. Ancora Advisors LLC now owns 1,705,788 shares of the company's stock worth $19,190,000 after buying an additional 1,374,231 shares during the last quarter. DekaBank Deutsche Girozentrale grew its position in Enhabit by 12,146.2% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 244,924 shares of the company's stock valued at $2,543,000 after buying an additional 242,924 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Enhabit by 25.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company's stock valued at $10,003,000 after buying an additional 193,675 shares during the last quarter.
About Enhabit
(
Get Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
